<< Back to News

System Formulary Update
Topical Anti-Infective

Situation

The Topical Anti-Infective class review standardization was approved in July 2022.

Background

The following products were reviewed: clindamycin lotion, clindamycin topical gel, clindamycin vaginal cream, clindamycin solution, gentamicin cream, gentamicin ointment, metronidazole topical gel, metronidazole vaginal gel, mupirocin cream, mupirocin ointment, mupirocin irrigation.

Assessment/Recommendations

System P&T voted to include the following products on the UNC Health System Drug Formulary:

• Clindamycin 1% lotion
• Clindamycin 1% topical gel (30 g)
• Gentamicin 0.1% topical cream
• Metronidazole 0.75% vaginal gel
• Mupirocin 2% topical ointment
• Mupirocin 0.44 mg/mL nasal irrigation (extemporaneous)

As a result, the following products will be removed from the inpatient drug formulary:

• Clindamycin 1% solution
• Clindamycin 1% topical gel (75 mL)
• Clindamycin 2% vaginal cream
• Erythromycin-benzoyl peroxide 3%-5% topical gel
• Gentamicin 0.1% topical ointment
• Metronidazole 0.75% topical gel
• Metronidazole 1% topical gel
• Mupirocin 2% topical cream
• Mupirocin 0.5% nasal spray (extemporaneous)
• Mupirocin 0.75% nasal spray (extemporaneous)
• Retapamulin 1% ointment

Formulary/Epic changes will Go-Live on Tuesday, September 6, 2022.